Clinical Trial Detail

NCT ID NCT02529813
Title CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute leukemia

chronic lymphocytic leukemia

acute lymphoblastic leukemia

CLL/SLL

non-Hodgkin lymphoma

Therapies

Cyclophosphamide + Fludarabine + Tisagenlecleucel

Age Groups: child senior adult

No variant requirements are available.